X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs CADILA HEALTHCARE - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA CADILA HEALTHCARE GLENMARK PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 14.2 36.3 39.2% View Chart
P/BV x 4.0 9.4 42.6% View Chart
Dividend Yield % 0.3 0.7 48.7%  

Financials

 GLENMARK PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-16
CADILA HEALTHCARE
Mar-16
GLENMARK PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,262454 277.7%   
Low Rs672305 220.5%   
Sales per share (Unadj.) Rs270.696.1 281.5%  
Earnings per share (Unadj.) Rs24.914.9 167.3%  
Cash flow per share (Unadj.) Rs34.417.8 193.1%  
Dividends per share (Unadj.) Rs2.003.20 62.5%  
Dividend yield (eoy) %0.20.8 24.5%  
Book value per share (Unadj.) Rs151.352.3 289.5%  
Shares outstanding (eoy) m282.161,023.74 27.6%   
Bonus/Rights/Conversions -FV5:1-  
Price / Sales ratio x3.63.9 90.5%   
Avg P/E ratio x38.925.5 152.3%  
P/CF ratio (eoy) x28.121.3 132.0%  
Price / Book Value ratio x6.47.3 88.0%  
Dividend payout %8.021.5 37.4%   
Avg Mkt Cap Rs m272,778388,458 70.2%   
No. of employees `00010.015.4 64.9%   
Total wages/salary Rs m13,78213,317 103.5%   
Avg. sales/employee Rs Th7,614.96,371.1 119.5%   
Avg. wages/employee Rs Th1,374.8862.4 159.4%   
Avg. net profit/employee Rs Th700.2986.1 71.0%   
INCOME DATA
Net Sales Rs m76,34098,376 77.6%  
Other income Rs m356941 37.9%   
Total revenues Rs m76,69699,317 77.2%   
Gross profit Rs m14,17223,829 59.5%  
Depreciation Rs m2,6913,022 89.1%   
Interest Rs m1,789486 368.1%   
Profit before tax Rs m10,04821,262 47.3%   
Minority Interest Rs m0-300 0.0%   
Prior Period Items Rs m05 0.0%   
Extraordinary Inc (Exp) Rs m0-25 0.0%   
Tax Rs m3,0285,716 53.0%   
Profit after tax Rs m7,01915,226 46.1%  
Gross profit margin %18.624.2 76.6%  
Effective tax rate %30.126.9 112.1%   
Net profit margin %9.215.5 59.4%  
BALANCE SHEET DATA
Current assets Rs m59,09644,376 133.2%   
Current liabilities Rs m40,01834,071 117.5%   
Net working cap to sales %25.010.5 238.6%  
Current ratio x1.51.3 113.4%  
Inventory Days Days7554 139.2%  
Debtors Days Days11962 191.2%  
Net fixed assets Rs m39,07547,896 81.6%   
Share capital Rs m2821,024 27.6%   
"Free" reserves Rs m30,28148,746 62.1%   
Net worth Rs m42,70353,519 79.8%   
Long term debt Rs m24,8738,964 277.5%   
Total assets Rs m111,026100,163 110.8%  
Interest coverage x6.644.7 14.8%   
Debt to equity ratio x0.60.2 347.8%  
Sales to assets ratio x0.71.0 70.0%   
Return on assets %7.915.7 50.6%  
Return on equity %16.428.4 57.8%  
Return on capital %17.534.3 51.1%  
Exports to sales %43.345.3 95.6%   
Imports to sales %7.45.9 125.2%   
Exports (fob) Rs m33,04444,537 74.2%   
Imports (cif) Rs m5,6725,838 97.2%   
Fx inflow Rs m36,94544,881 82.3%   
Fx outflow Rs m61,0669,069 673.4%   
Net fx Rs m-24,12235,812 -67.4%   
CASH FLOW
From Operations Rs m3,44919,938 17.3%  
From Investments Rs m-8,802-9,039 97.4%  
From Financial Activity Rs m6,986-9,527 -73.3%  
Net Cashflow Rs m9341,372 68.1%  

Share Holding

Indian Promoters % 48.3 74.8 64.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 8.3 83.1%  
FIIs % 34.4 5.9 583.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 11.0 95.5%  
Shareholders   56,727 44,069 128.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   PANACEA BIOTECH  DISHMAN PHARMA  FULFORD INDIA  NATCO PHARMA  DIVIS LABORATORIES  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Steady Despite North Korea Threat(RoundUp)

Global financial markets ended the week on a flat note despite North Korea once again threatening to test a hydrogen bomb in the Pacific Ocean.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 22, 2017 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS